Showing results (371-380 of 673) with videos related to
Sort By:
Pageof 68
HIV Clinical Trials|November 3, 2011
Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysisS Krishnan, K Wu, M Smurzynski, et al.HIV Clinical Trials|February 3, 2006
Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV centerIvana Maida, Vincent Soriano, Belén Ramos, et al.HIV Clinical Trials|January 24, 2006
Psychological distress and physical pain appear to have no short-term adverse impact on plasma HIV-1 RNA levels in patients on successful HAARTRichard E Nettles, Tara L Keiffer, Joseph Cofrancesco, et al.HIV Clinical Trials|November 29, 2007
Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolitesDavid B Hall, Thomas R MacgregorHIV Clinical Trials|January 25, 2008
The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patientsLisa M Demeter, A Lisa Mukherjee, Robin DiFrancesco, et al.HIV Clinical Trials|November 29, 2007
Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected menJames D Scott, Peter R Wolfe, Peter Anderson, et al.HIV Clinical Trials|November 17, 2016
Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacyTamara M Johnson, Raymund Sison, James P Fallon, et al.HIV Clinical Trials|April 30, 2004
Interferon-gamma therapy activates human monocytes for enhanced phagocytosis of Mycobacterium avium complex in HIV-infected individualsKatherine Kedzierska, Geza Paukovics, Amanda Handley, et al.HIV Clinical Trials|April 30, 2004
A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individualsSarah L Pett, Lisa A Williams, Richard O Day, et al.HIV Clinical Trials|April 30, 2004
Initial therapy for human immunodeficiency virus: broadening the optionsMichael SensionPageof 68